Dr. Anusha Vallurupalli, MD

Dr. Vallurupalli practices at Emory University Hospital Midtown in Atlanta, Georgia, part of Emory University.

Dr. Vallurupalli's NPI, 1700107745, was assigned on June 14, 2010. Dr. Vallurupalli holds Georgia license 96046.

Dr. Vallurupalli's primary practice is Emory University Hospital Midtown, at 550 Peachtree Street, NE, Atlanta, GA 30308 in Fulton County. The practice phone is (404) 686-2450.

Dr. Vallurupalli's primary practice is Emory University Hospital Midtown in Atlanta, Georgia, part of Emory University. Dr. Vallurupalli is also affiliated with Emory University Hospital. The medical group on file is Emory Clinic. Dmand AI also links Dr. Vallurupalli to 3 more hospitals, 1 clinical lab and 1 ambulatory surgery center, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Vallurupalli practices, 7 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Vallurupalli's primary specialty in the NPI Registry, under taxonomy code 207RH0000X. The record also lists hematology. Dmand AI has Dr. Vallurupalli's licenses on file in 4 states: Georgia, Florida, Louisiana and Oregon.

CMS data shows 704 Medicare services from Dr. Vallurupalli across 6 procedure codes in 2024, for 185 Medicare patients. Medicare paid $35,642 for them. Every service was in an office.

CMS counts 185 Medicare patients who saw Dr. Vallurupalli in 2024. The largest group is 65 to 74, with 74 patients. 75% of them have high blood pressure, and 74% have high cholesterol. 14% are also on Medicaid. Their average risk score is 2.19, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Vallurupalli's median patient age at 69, with 68% women.

In 2024, Dr. Vallurupalli wrote 770 Medicare Part D claims for 172 patients. 79% of them were for generic drugs. CMS names the drug for 473 of them, across 17 drugs with 11 or more claims each, at $632,922 in total drug cost. In 2023, CMS named 168 claims across 8 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 95 out of 100 for Dr. Vallurupalli for performance year 2024, reported through an alternative payment model (APM). Dr. Vallurupalli accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Vallurupalli as offering telehealth.

CMS Open Payments shows 50 general payments to Dr. Vallurupalli from 17 drug and device companies from 2016 to 2025. Travel and lodging make up the largest share, 73% of the total. Kite Pharma, Inc. paid the most, $4,294.